Calidi Biotherapeutics (CLDI) Assets Average (2022 - 2026)

Calidi Biotherapeutics has reported Assets Average for 5 years, with the latest figure at $8.0 million in Q2 2026.

• On a quarterly basis, Assets Average fell 34.22% year-over-year to $8.0 million in Q2 2026; TTM through Jun 2026 was $8.0 million, a 34.22% decrease from a year earlier, with the FY2025 full-year figure at $11.5 million, down 4.8% from the prior year.
• Assets Average was $8.0 million for Q2 2026 at Calidi Biotherapeutics, down from $11.4 million in the prior quarter.
• The five-year high for Assets Average was $231.5 million in Q1 2022, with the low at $3.3 million in Q3 2024.
• Average Assets Average over 5 years is $48.1 million, with a median of $14.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Assets Average tumbled 91.48% in 2024, then soared 250.16% in 2025.
• Over 5 years, Assets Average stood at $22.4 million in 2022, then plunged by 36.08% to $14.3 million in 2023, then declined by 27.15% to $10.4 million in 2024, then climbed by 9.82% to $11.4 million in 2025, then dropped by 29.82% to $8.0 million in 2026.
• The last three Assets Average figures came in at $8.0 million (Q2 2026), $11.4 million (Q4 2025), and $11.7 million (Q3 2025), per Business Quant data.